Project Factsheets

Antibiotic distribution and recovery in tissue

Antimicrobial Resistance Accelerator

Collaboration for prevention and treatment of MDR bacterial infections

European regimen accelerator for tuberculosis

Novel Gram-negative antibiotic now

Predicting the impact of monoclonal antibodies & vaccines on antimicrobial resistance

Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugs

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments